Bone Therapeutics Treats First Patients in Phase III Knee Osteoarthritis Study
The JTA-004 Phase III study is approved in five of seven territories. These are the first patients treated after resumption...
The JTA-004 Phase III study is approved in five of seven territories. These are the first patients treated after resumption...
Carmell will begin enrolling in a pivotal clinical program for Plasma-based Bioactive Material used in long-bone fractures as an adjunctive...
This represents the first calcium matrix to receive European approval as an antibiotic carrier for use in bone and soft...
New preclinical data confirms that local delivery of a bisphosphonate in combination with CERAMENT can regenerate cancellous bone....
InGeneron announces favorable study results using regenerative autologous adipose-derived cells that are prepared with the Transpose® RT System for treatment of...
BBS-Bioactive Bone Substitutes' patent application protecting ARTEBONE® bone graft substitute has been accepted in the U.S. ...
Bone Therapeutics received regulatory approvals for next studies of both of its lead therapeutic candidates to treat osteoarthritic knee pain....
BONESUPPORT will submit a De Novo application for approval of CERAMENT® G in the treatment of osteomyelitis. ...
Kuros Biosurgery was granted U.S. patents related to the MagnetOs product line and parathyroid hormones containing matrices for spinal fusion....
Study results support the use of NuVasive's Attrax® Putty as a standalone bone graft substitute for autograft in instrumented thoracolumbar...
Login
Register for a free account
As a guest member you get access to more articles and videos every month.